Stockholm, Sweden, April 30, 2026 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced its participation in the Pediatric Endocrine Society (PES) Annual Meeting, taking place April 30 to May 3, 2026, in San Francisco, CA, USA.
Egetis will engage with the pediatric endocrinology community through multiple scientific and educational activities during the meeting. The Company will host a disease awareness booth (#321), providing information on MCT8 deficiency (Allan-Herndon-Dudley syndrome) and ongoing efforts to increase disease awareness, enhance clinician education, and support earlier diagnosis.
Anny Bedard, President North America at Egetis, said: “The Pediatric Endocrine Society meeting in the U.S. represents an important opportunity for Egetis to connect with a highly relevant clinical audience. Pediatric endocrinologists play a critical role in the identification, diagnosis, and management of patients with rare metabolic and endocrine disorders, and we look forward to sharing our data and increasing awareness of MCT8 deficiency.”
In addition, Egetis will present a scientific poster titled “Real-world data-driven insights uncovering clinical and biochemical patterns that inform the identification of undiagnosed patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome)”, underscoring opportunities to improve early recognition and reduce time to diagnosis.
The Company will also deliver an oral presentation titled “Effects of tiratricol withdrawal in monocarboxylate transporter 8 (MCT8) deficiency: The ReTRIACt trial,” adding to the growing body of clinical evidence supporting the safety and efficacy profile of tiratricol.